GSK opens new £56 million respiratory meds manufacturing facility

18 April 2016

UK pharma major GlaxoSmithKline (LSE: GSK) today opens a £56 million ($79.4 million) state of the art manufacturing facility, creating 150 new jobs in the UK, in response to demand for GSK’s portfolio of respiratory medicines delivered by the innovative Ellipta inhaler.

It is the latest expansion for Ellipta manufacturing at Ware, with investment totalling over £100 million over the past five years. The new facility opening today is expected to nearly double production of Ellipta inhalers at Ware to at least 37 million per year by 2017, 95% of which will be exported.

The Ellipta inhaler is a multi-dose dry powder inhaler (DPI) developed to deliver GSK’s portfolio of once-daily respiratory medicines. It is the result of more than 10 years of design and development by a team of more than 200 scientists and engineers, the company noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK